LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer

Figure 1 Long non-coding RNA MEG3 in tissue, serum and cell lines. A: Relative levels of MEG3 in CRC tissues and normal tissues; B: Relative levels of MEG3 in cell lines; C: Relative levels of serum MEG3 in CRC patients and healthy controls. All data were repeated three times; ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. CRC: Colorectal cancer; MEG3: Maternally expressed gene 3.

Figure 2 Results of MEG3 in the diagnosis of colorectal cancer. A: Serum maternally expressed gene 3 levels in the sample of 1 d and 1 mo after surgery; B: Receiver-operator characteristic curve for colorectal cancer detection. All data were repeated three times; ^bP < 0.01. 1 d: The 1st d after surgical removal of the tumor; 1 mo: The 30th d after surgical removal of the tumor; ROC: Receiver-operating characteristic curve; AUC: Area under curve; MEG3: Maternally expressed gene 3.

Figure 3 Results of MEG3 in the prognosis of CRC in Kaplan‑Meier survival curves. All data were repeated three times. CRC: Colorectal cancer; MEG3: Maternally expressed gene 3.

Figure 4 Result of transfection efficacies. A: Transfection efficacies of pcDNA MEG3 in HCT-116 cells; B: Transfection efficacies of pcDNA MEG3 in HT29 cells. All data were repeated three times; ^bP < 0.01, ^cP < 0.001. MEG3: Maternally expressed gene 3.

Figure 5 The role of MEG3 in cell function. A: Cell proliferation in HCT-116 cells after overexpression of MEG3; B: Cell proliferation in HT29 cells after overexpression of MEG3; C: Apoptosis in HCT-116 cells after overexpression of MEG; D: Apoptosis in HT29 cells after overexpression of MEG; E: Protein expression of ADAR1 after overexpression of MEG3 in HCT-116 cells; F: Protein expression of ADAR1 after overexpression of MEG3 in HT29 cells. All data were repeated three times; ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. OD: Optical density; ADAR1: Adenosine deaminase acting on RNA 1; MEG3: Maternally expressed gene 3.